Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Medicure Inc. stock logo
MPH
Medicure
C$1.28
-1.5%		C$1.20
C$0.85
▼
C$1.43
C$13.57M0.4426953,028 shs6,032 shs
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
$1.54
+1.3%		$1.56
$1.34
▼
$3.20
$80.82M0.0474,303 shs14,672 shs
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Medicure Inc. stock logo
MPH
Medicure
0.00%-5.88%+23.08%+16.36%+21.90%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
0.00%+1.32%+4.05%-5.52%-37.40%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Medicure Inc. stock logo
MPH
Medicure
C$1.28
-1.5%		C$1.20
C$0.85
▼
C$1.43
C$13.57M0.4426953,028 shs6,032 shs
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
$1.54
+1.3%		$1.56
$1.34
▼
$3.20
$80.82M0.0474,303 shs14,672 shs
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Medicure Inc. stock logo
MPH
Medicure
0.00%-5.88%+23.08%+16.36%+21.90%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
0.00%+1.32%+4.05%-5.52%-37.40%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Medicure Inc. stock logo
MPH
Medicure
0.00
N/AN/AN/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
2.40
Hold$5.67267.97% Upside

Current Analyst Ratings Breakdown

Latest OKYO, MPH, FARN, and 4BB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/13/2026
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$7.00 ➝ $5.00
(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Medicure Inc. stock logo
MPH
Medicure
C$31.32M0.43C$0.51 per share2.49C$1.11 per share1.15
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/AN/AN/AN/A$0.30 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Medicure Inc. stock logo
MPH
Medicure
-C$2.03M-C$0.65N/AN/AN/A-23.23%-54.73%-5.63%N/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
-$8.95MN/AN/AN/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Medicure Inc. stock logo
MPH
Medicure
N/A2.24%N/AN/AN/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Medicure Inc. stock logo
MPH
Medicure
6.02
0.97
1.29
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/A
2.43
2.43

Institutional Ownership

CompanyInstitutional Ownership
Medicure Inc. stock logo
MPH
Medicure
4.85%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
2.97%

Insider Ownership

CompanyInsider Ownership
Medicure Inc. stock logo
MPH
Medicure
26.68%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
40.46%
CompanyEmployeesShares OutstandingFree FloatOptionable
Medicure Inc. stock logo
MPH
Medicure
N/A10.44 millionN/ANot Optionable
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
752.48 million31.25 millionNot Optionable

Recent News About These Companies

Critical Review: Akari Therapeutics (NASDAQ:AKTX) vs. OKYO Pharma (NASDAQ:OKYO)
August 22 at 2:29 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30975697
Short Interest in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Expands By 223.4%
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/short-interest-in-okyo-pharma-limited-sponsored-adr-nasdaqokyo-expands-by-2234-2026-08-13/
OKYO Pharma (OKYO) Expected to Post Quarterly Earnings on Monday
August 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/okyo-pharma-okyo-expected-to-post-quarterly-earnings-on-monday-2026-08-03/
OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer
July 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/28/3334117/0/en/okyo-pharma-announces-purchase-of-shares-by-chief-scientific-officer.html
OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026
July 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/27/3333362/0/en/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026.html
OKYO Pharma outlines path to phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain
July 25, 2026  |  ophthalmologytimes.comO
OKYO Pharma Announces Purchase of Shares by Director
July 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/23/3332413/0/en/okyo-pharma-announces-purchase-of-shares-by-director.html
OKYO Pharma Announces Purchase of Shares by Chief Executive Officer
July 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/23/3331994/0/en/okyo-pharma-announces-purchase-of-shares-by-chief-executive-officer.html
OKYO Pharma Announces Purchase of Shares by Chairman
July 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/22/3331587/0/en/okyo-pharma-announces-purchase-of-shares-by-chairman.html
OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director
July 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/22/3331510/0/en/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director.html
OKYO Pharma Announces Purchase of Shares by Chief Medical Officer
July 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/22/3331223/0/en/okyo-pharma-announces-purchase-of-shares-by-chief-medical-officer.html
OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
July 21, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/okyo-pharma-to-present-at-the-h-c-wainwright-6th-annual-ophthalmology-virtual-conference-1036345995
OKYO Pharma Announces Purchase of Shares by Chairman
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330300/0/en/okyo-pharma-announces-purchase-of-shares-by-chairman.html
Small caps: Replenish Nutrients, OKYO Pharma, EDM Resources
July 20, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1095724?snapi
OKYO Pharma files annual report, highlights cash position and Phase 3 trial plans
July 20, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1095701?snapi
OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans
July 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/20/3329597/0/en/okyo-pharma-announces-filing-of-annual-report-with-strengthened-cash-position-and-accelerated-phase-3-plans.html
OKYO Pharma to Highlight Neuropathic Corneal Pain Program at Piper Sandler Virtual Ophthalmology Symposium
July 14, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/OKYO/pressreleases/3181476/okyo-pharma-to-highlight-neuropathic-corneal-pain-program-at-piper-sandler-virtual-ophthalmology-symposium/
OKYO Pharma announces positive feedback from US FDA Type D Meeting and accelerates urcosimod into global phase 3 trial for NCP
July 11, 2026  |  pharmabiz.comP
OKYO Pharma advances toward Phase 3 FDA trial - ICYMI
July 11, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1095285?snapi
Phase 3 trial to study urcosimod in neuropathic corneal pain
July 10, 2026  |  healio.comH
Okyo Pharma
July 10, 2026  |  fool.comhttps://www.fool.com/quote/nasdaq/okyo/

Media Sentiment Over Time

Medicure stock logo

Medicure CVE:MPH

C$1.28 -0.02 (-1.54%)
As of 08/21/2026 03:27 PM Eastern

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.

OKYO Pharma stock logo

OKYO Pharma NASDAQ:OKYO

$1.54 +0.02 (+1.32%)
As of 08/21/2026 04:00 PM Eastern

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas